Myriad Genetics

According to Morgan Stanley, Myriad Genetics (NASDAQ: MYGN) saw a strong 3Q. Morgan Stanley said that an unexpected growth mix from oncology acceleration (~14% vs 5-6% in FY1H11) raises questions about sustainability, which will be the primary debate exiting the quarter. “Guidance implies some...

According to J.P. Morgan, Myriad Genetics (NASDAQ: MYGN) risk / reward is balanced. J.P. Morgan reported that it recently conducted three physician surveys and a buy-side investor survey as part of a re-evaluation of our investment thesis on Myriad Genetics (MYGN), which remains highly...

Global Hunter is out with its report today on Myriad Genetics (NASDAQ: MYGN), maintaining Neutral. In a note to clients, Global Hunter writes, "Myriad Genetics announced a partnership with BioMarin Pharmaceuticals (NASDAQ: BMRN) allowing it to use Myriad's proprietary BRACAnalysis molecular...

According to Goldman Sachs, Myriad Genetics (NASDAQ: MYGN) oral arguments helf few surprises yesterday. Goldman Sachs reported that oral arguments in the U.S. Circuit Court of Appeals for the Federal Circuit case of Association of Molecular Pathology, et al. v. United States Patent and Trademark...

Piper Jaffray has raised the price target on Myriad Genetics (NASDAQ: MYGN) from $18 to $20 and maintains its Neutral rating.

Myriad Genetics, Inc. (NASDAQ: MYGN) reported revenue and EPS above PiperJaffray's estimates and FY2011 guidance calls for revenue growth of 4.8-10.3% to $380-400M and EPS of $0.95-1.00, short of PiperJaffray's estimates. PiperJaffray maintains its "neutral" rating for Myriad Genetics but has...